Bevacizumab

Generic Name
Bevacizumab
Brand Names
Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi
Drug Type
Biotech
Chemical Formula
-
CAS Number
216974-75-3
Unique Ingredient Identifier
2S9ZZM9Q9V
Background

There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
...

Indication

As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer;...

Associated Conditions
Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
Associated Therapies
First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment
Clinical Trials
Related News

Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer

First Posted Date
2006-08-21
Last Posted Date
2017-05-15
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
32
Registration Number
NCT00366457
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer

First Posted Date
2006-08-17
Last Posted Date
2021-04-13
Lead Sponsor
NSABP Foundation Inc
Target Recruit Count
45
Registration Number
NCT00365417
Locations
🇺🇸

NSABP Foundation, Inc., Pittsburgh, Pennsylvania, United States

Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer

First Posted Date
2006-08-15
Last Posted Date
2012-08-23
Lead Sponsor
Sanofi
Target Recruit Count
73
Registration Number
NCT00364611
Locations
🇺🇸

Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States

Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer

First Posted Date
2006-08-08
Last Posted Date
2017-02-07
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
35
Registration Number
NCT00361231
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site

First Posted Date
2006-08-04
Last Posted Date
2013-12-04
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
60
Registration Number
NCT00360360
Locations
🇺🇸

Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States

🇺🇸

Graves-Gilbert Clinic, Bowling Green, Kentucky, United States

🇺🇸

Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States

and more 6 locations

A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer

First Posted Date
2006-07-26
Last Posted Date
2015-10-15
Lead Sponsor
Amgen
Target Recruit Count
282
Registration Number
NCT00356681

Bevacizumab and Radiation Therapy for Sarcomas

First Posted Date
2006-07-25
Last Posted Date
2017-05-19
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
20
Registration Number
NCT00356031
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)

First Posted Date
2006-07-25
Last Posted Date
2011-10-17
Lead Sponsor
Sanofi
Target Recruit Count
53
Registration Number
NCT00356122
Locations
🇺🇸

Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States

Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients

First Posted Date
2006-07-20
Last Posted Date
2011-10-21
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
49
Registration Number
NCT00354978
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Lyndon Baines Johnson General Hospital, Houston, Texas, United States

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma

First Posted Date
2006-07-14
Last Posted Date
2014-07-22
Lead Sponsor
Duke University
Target Recruit Count
20
Registration Number
NCT00352521
Locations
🇺🇸

Duke Comprehensive Cancer Center, Durham, North Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy